Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.75
NAS:ARRY's Cash-to-Debt is ranked lower than
76% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:ARRY: 1.75 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ARRY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.49  Med: 1.66 Max: No Debt
Current: 1.75
Equity-to-Asset 0.04
NAS:ARRY's Equity-to-Asset is ranked lower than
92% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:ARRY: 0.04 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ARRY' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.46  Med: 0.23 Max: 0.93
Current: 0.04
-1.46
0.93
Piotroski F-Score: 4
Altman Z-Score: -1.07
Beneish M-Score: -4.14
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -67.67
NAS:ARRY's Operating Margin % is ranked higher than
55% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:ARRY: -67.67 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ARRY' s Operating Margin % Range Over the Past 10 Years
Min: -410.11  Med: -63.65 Max: 6.34
Current: -67.67
-410.11
6.34
Net Margin % -77.44
NAS:ARRY's Net Margin % is ranked higher than
52% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:ARRY: -77.44 )
Ranked among companies with meaningful Net Margin % only.
NAS:ARRY' s Net Margin % Range Over the Past 10 Years
Min: -511.63  Med: -83.68 Max: 18.05
Current: -77.44
-511.63
18.05
ROE % -40646.49
NAS:ARRY's ROE % is ranked lower than
99.99% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:ARRY: -40646.49 )
Ranked among companies with meaningful ROE % only.
NAS:ARRY' s ROE % Range Over the Past 10 Years
Min: -3933.07  Med: -132.15 Max: 110.67
Current: -40646.49
-3933.07
110.67
ROA % -51.09
NAS:ARRY's ROA % is ranked lower than
67% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:ARRY: -51.09 )
Ranked among companies with meaningful ROA % only.
NAS:ARRY' s ROA % Range Over the Past 10 Years
Min: -99.03  Med: -51.46 Max: 5.6
Current: -51.09
-99.03
5.6
ROC (Joel Greenblatt) % -1375.06
NAS:ARRY's ROC (Joel Greenblatt) % is ranked lower than
62% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:ARRY: -1375.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ARRY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1410.82  Med: -321.97 Max: 297.05
Current: -1375.06
-1410.82
297.05
3-Year Revenue Growth Rate 39.40
NAS:ARRY's 3-Year Revenue Growth Rate is ranked higher than
67% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:ARRY: 39.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ARRY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -35.9  Med: -2.2 Max: 39.8
Current: 39.4
-35.9
39.8
3-Year EBITDA Growth Rate 2.90
NAS:ARRY's 3-Year EBITDA Growth Rate is ranked higher than
59% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NAS:ARRY: 2.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ARRY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -66.3  Med: 2.7 Max: 105.1
Current: 2.9
-66.3
105.1
3-Year EPS without NRI Growth Rate 1.40
NAS:ARRY's 3-Year EPS without NRI Growth Rate is ranked higher than
57% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. NAS:ARRY: 1.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ARRY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -50.5  Med: 1.4 Max: 55.7
Current: 1.4
-50.5
55.7
GuruFocus has detected 2 Warning Signs with Array BioPharma Inc $NAS:ARRY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ARRY's 30-Y Financials

Financials (Next Earnings Date: 2017-11-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ARRY Guru Trades in Q3 2016

Paul Tudor Jones 135,000 sh (New)
Joel Greenblatt 16,705 sh (New)
Jim Simons 424,452 sh (+2332.11%)
Ken Fisher 135,895 sh (+0.15%)
» More
Q4 2016

ARRY Guru Trades in Q4 2016

Steven Cohen 1,570,641 sh (New)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Ken Fisher 65,693 sh (-51.66%)
» More
Q1 2017

ARRY Guru Trades in Q1 2017

Caxton Associates 15,900 sh (New)
Ken Fisher 78,014 sh (+18.76%)
Steven Cohen 500,000 sh (unchged)
Steven Cohen 1,277,900 sh (-18.64%)
» More
Q2 2017

ARRY Guru Trades in Q2 2017

Paul Tudor Jones 73,373 sh (New)
Jim Simons 990,441 sh (New)
Steven Cohen 2,406,000 sh (+88.28%)
Ken Fisher 134,180 sh (+71.99%)
Caxton Associates Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ARRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-06-30 Add 71.99%$6.96 - $9.07 $ 8.777%134,180
Ken Fisher 2017-03-31 Add 18.76%$8.56 - $12.56 $ 8.77-18%78,014
Ken Fisher 2016-12-31 Reduce -51.66%$5.38 - $8.8 $ 8.7719%65,693
Joel Greenblatt 2016-12-31 Sold Out $5.38 - $8.8 $ 8.7719%0
Ken Fisher 2016-09-30 Add 0.15%$3.17 - $6.75 $ 8.77127%135,895
Joel Greenblatt 2016-09-30 New Buy$3.17 - $6.75 $ 8.77127%16,705
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NYSE:EBS, NAS:LXRX, NAS:INVA, NAS:CORT, NAS:XLRN, NAS:HALO, NAS:GBT, NYSE:CBM, NAS:RGEN, NAS:MYOK, NAS:BPMC, NAS:ESPR, NAS:OMER, NAS:XNCR, NAS:ACOR, NAS:DERM, NAS:AIMT, NAS:FOLD, NAS:AKCA, NAS:AMRI » details
Traded in other countries:AR2.Germany,
Headquarter Location:USA
Array BioPharma Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases.

Array BioPharma Inc was incorporated in Delaware on February 6, 1998. It is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The Company's proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. In addition, pharmaceutical and biotechnology companies partner with the Company to discover and develop drug candidates across various therapeutic areas. The Company's proprietary clinical programs include three cancer drugs, binimetinib (MEK162 / wholly-owned), encorafenib (LGX818 / wholly-owned) and selumetinib (partnered with AstraZeneca. The Company's internal drug discovery programs include inhibitors that target Trk receptors for the treatment of oncology and other indications. The Company competes with companies that are engaged in the research and discovery, licensing, development and commercialization of drug candidates, including large pharmaceutical companies with internal discovery and development functions, biotech companies with competing products in the therapeutic areas it is targeting and contract research organizations that perform many of the functions it performs under its collaborations. The Company is subject to substantial regulation by governmental agencies in the U.S. and other countries.

Ratios

vs
industry
vs
history
PB Ratio 127.10
ARRY's PB Ratio is ranked lower than
98% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. ARRY: 127.10 )
Ranked among companies with meaningful PB Ratio only.
ARRY' s PB Ratio Range Over the Past 10 Years
Min: 3.52  Med: 14.63 Max: 131.45
Current: 127.1
3.52
131.45
PS Ratio 9.42
ARRY's PS Ratio is ranked higher than
59% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. ARRY: 9.42 )
Ranked among companies with meaningful PS Ratio only.
ARRY' s PS Ratio Range Over the Past 10 Years
Min: 1.44  Med: 7.46 Max: 24.4
Current: 9.42
1.44
24.4
EV-to-EBIT -13.43
ARRY's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. ARRY: -13.43 )
Ranked among companies with meaningful EV-to-EBIT only.
ARRY' s EV-to-EBIT Range Over the Past 10 Years
Min: -44  Med: -5.9 Max: 320.9
Current: -13.43
-44
320.9
EV-to-EBITDA -13.70
ARRY's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. ARRY: -13.70 )
Ranked among companies with meaningful EV-to-EBITDA only.
ARRY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -76.5  Med: -6.5 Max: 165.9
Current: -13.7
-76.5
165.9
Current Ratio 3.88
ARRY's Current Ratio is ranked lower than
55% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. ARRY: 3.88 )
Ranked among companies with meaningful Current Ratio only.
ARRY' s Current Ratio Range Over the Past 10 Years
Min: 0.89  Med: 2.95 Max: 7.45
Current: 3.88
0.89
7.45
Quick Ratio 3.88
ARRY's Quick Ratio is ranked lower than
52% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. ARRY: 3.88 )
Ranked among companies with meaningful Quick Ratio only.
ARRY' s Quick Ratio Range Over the Past 10 Years
Min: 0.89  Med: 2.95 Max: 5.97
Current: 3.88
0.89
5.97
Days Sales Outstanding 75.68
ARRY's Days Sales Outstanding is ranked lower than
55% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. ARRY: 75.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARRY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.61  Med: 50.33 Max: 497.21
Current: 75.68
4.61
497.21
Days Payable 89.06
ARRY's Days Payable is ranked higher than
69% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. ARRY: 89.06 )
Ranked among companies with meaningful Days Payable only.
ARRY' s Days Payable Range Over the Past 10 Years
Min: 37.58  Med: 76.12 Max: 159.87
Current: 89.06
37.58
159.87

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.00
ARRY's 3-Year Average Share Buyback Ratio is ranked higher than
66% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. ARRY: -9.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARRY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -111.3  Med: -11.65 Max: -4.2
Current: -9
-111.3
-4.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 438.50
ARRY's Price-to-Net-Current-Asset-Value is ranked lower than
97% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. ARRY: 438.50 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ARRY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.24  Med: 7.03 Max: 422.5
Current: 438.5
2.24
422.5
Price-to-Tangible-Book 127.10
ARRY's Price-to-Tangible-Book is ranked lower than
98% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ARRY: 127.10 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ARRY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.14  Med: 4.56 Max: 122.46
Current: 127.1
1.14
122.46
Price-to-Median-PS-Value 1.27
ARRY's Price-to-Median-PS-Value is ranked lower than
61% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ARRY: 1.27 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ARRY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 0.87 Max: 2.62
Current: 1.27
0.23
2.62
Earnings Yield (Greenblatt) % -7.45
ARRY's Earnings Yield (Greenblatt) % is ranked higher than
51% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. ARRY: -7.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ARRY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -95.2  Med: -15 Max: 5.1
Current: -7.45
-95.2
5.1

More Statistics

Revenue (TTM) (Mil) $150.85
EPS (TTM) $ -0.73
Beta1.58
Short Percentage of Float19.05%
52-Week Range $3.10 - 13.40
Shares Outstanding (Mil)171.44

Analyst Estimate

Jun18
Revenue (Mil $)
EPS ($) -1.33
EPS without NRI ($) -1.33
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ARRY

Headlines

Articles On GuruFocus.com
Array BioPharma Appoints Curtis Oltmans As General Counsel Aug 14 2017 
Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2017 On A Aug 03 2017 
Amgen And Array BioPharma Announce Preclinical License And Collaboration Agreement In Inflammation Jul 18 2017 
Array Biopharma To Present At The Goldman Sachs 38th Annual Global Healthcare Conference Jun 01 2017 
Array BioPharma And Ono Pharmaceutical Co., Ltd. Announce A License, Development And Commercializati May 31 2017 
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration May 30 2017 
Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2017 May 10 2017 
Array BioPharma Announces Positive Top-Line Results from Part 2 of the Phase 3 COLUMBUS Study of Bin May 09 2017 
Array BioPharma Announces Strategic Collaboration with Merck May 08 2017 
Array Biopharma To Report Financial Results For The Third Quarter Of Fiscal 2017 On May 10, 2017 May 03 2017 

More From Other Websites
Edited Transcript of ARRY earnings conference call or presentation 9-Aug-17 1:00pm GMT Aug 16 2017
3 Big Stock Charts for Wednesday: Amazon.com, Inc. (AMZN), Array Biopharma Inc (ARRY) and Paychex,... Aug 16 2017
See what the IHS Markit Score report has to say about Array Biopharma Inc. Aug 16 2017
Array BioPharma Appoints Curtis Oltmans As General Counsel Aug 14 2017
Array BioPharma, Inc. :ARRY-US: Earnings Analysis: 2017 By the Numbers : August 14, 2017 Aug 14 2017
Today's Research Reports on Trending Tickers: Array BioPharma Inc. and 22nd Century Group Inc. Aug 14 2017
Array BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : ARRY-US : August 10,... Aug 10 2017
IHS Markit Score Update: Drop in demand for ETFs holding Array Biopharma Inc is a negative sign for... Aug 10 2017
Array BioPharma reports 4Q loss Aug 09 2017
Investor Network: Array BioPharma Inc. to Host Earnings Call Aug 09 2017
Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2017 Aug 09 2017
Here's Why Array BioPharma Inc. Fell 13.7% in July Aug 07 2017
Array BioPharma, Inc. – Value Analysis (NASDAQ:ARRY) : August 5, 2017 Aug 04 2017
Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2017 On... Aug 03 2017
Array BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : ARRY-US : July 24,... Jul 24 2017
New Strong Sell Stocks for July 20th Jul 20 2017
Colorado biotech makes deal with industry giant Jul 18 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}